1. Bayer CEO: Executive Team has Board's Backing Despite Key Loss in Roundup Court

    Bayer CEO: Executive Team has Board's Backing Despite Key Loss in Roundup Court

    Last week, Bayer lost phase one of the first Roundup bellwether trial, which could set the tone for more than 11,200 others waiting in the wings. And Bayer's shares took an immediate beating...

    Read Full Article

    Login to comment.

  1. Categories

    1. BoardProspects Features:

      BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, In the News, Partner Publications, Sponsored Content
  2. Quotes

    1. The share price is significantly impacted by the legal cases related to glyphosate in America, the discounts are greatly exaggerated.
    2. We are disappointed with the jury's initial decision, but we continue to believe firmly that the science confirms that glyphosate-based herbicides do not cause cancer.
    3. This looks like 2-0 plaintiffs, and clearly not helpful for the overall payout calculus and resolution of the litigation, hardening the resolve of plaintiffs to pursue the company versus moving towards a settlement.
    4. We are confident the evidence in phase two will show that Monsanto's conduct has been appropriate and that the company should not be liable for Mr. Hardeman's cancer.
  3. Topics Mentioned